Inactive Instrument

Analyst Reco. Pluristem Therapeutics Nasdaq

Equities

Alliance Global Lowers Pluristem Therapeutics' Price Target to $4 From $9.50, Maintains Buy Rating	22-07-20	MT
PLURISTEM THERAPEUTICS : Alliance Global Starts Pluristem Therapeutics at Buy with $12.50 Price Target	21-05-04	MT
PLURISTEM THERAPEUTICS : Jefferies Downgrades Pluristem Therapeutics to Hold From Buy; Adjusts PT $6 From $16	20-12-10	MT
PLURISTEM THERAPEUTICS : HC Wainwright Adjusts Pluristem Therapeutics' Price Target to $9 From $15.50, Keeps Buy Rating	20-12-10	MT

No results for this search